Compare · LXRX vs NVO
LXRX vs NVO
Side-by-side comparison of Lexicon Pharmaceuticals Inc. (LXRX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LXRX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 219.3x LXRX ($835.1M).
- Over the past year, LXRX is up 157.1% and NVO is down 44.6% - LXRX leads by 201.6 points.
- LXRX has been more active in the news (9 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 5 for LXRX).
- Company
- Lexicon Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $1.90+0.26%
- $41.84+2.02%
- Market cap
- $835.1M
- $183.15B
- 1M return
- -5.25%
- -9.20%
- 1Y return
- +157.05%
- -44.55%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 9
- 8
- Recent ratings
- 5
- 25
Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LXRX
- Director Swain Judith L converted options into 89,312 shares, increasing direct ownership by 105% to 174,486 units (SEC Form 4)
- Director Sullivan Diane E. converted options into 89,312 shares, increasing direct ownership by 243% to 126,122 units (SEC Form 4)
- Director Sobecki Christopher J converted options into 89,312 shares, increasing direct ownership by 44% to 293,177 units (SEC Form 4)
- Director Cheung Ivan converted options into 89,312 shares (SEC Form 4)
- Director Amouyal Philippe converted options into 89,312 shares, increasing direct ownership by 31% to 374,486 units (SEC Form 4)
- Director Barker Sam L converted options into 89,312 shares, increasing direct ownership by 72% to 213,771 units (SEC Form 4)
- Director Debbane Raymond converted options into 89,312 shares, increasing direct ownership by 5% to 1,995,498 units (SEC Form 4)
- Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
- Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
- Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care